Eli Lilly and Company (LLY) TD Cowen 45th Annual Health Care Conference (Transcript)

Core Insights - Eli Lilly is focusing on key upcoming pipeline catalysts, particularly in the oncology sector and broader R&D initiatives [4]. Group 1: Pipeline Developments - The orforglipron program is highlighted as a significant upcoming catalyst, which is an oral small molecule GLP-1 nonpeptide agonist [5]. - The first study of the orforglipron program will focus on type 2 diabetes, while the second will target obesity [5]. - The ability to manufacture this oral small molecule at scale is emphasized as a critical advantage for the company [6].